IDiyas

For the Inventor, By the Inventor

Gaithersburg, MD, United States of America

Carl Thomas Wild

USPTO Granted Patents = 19 


Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 200(Granted Patents)


Location History:

  • Durham, NC (US) (1995 - 2007)
  • Gaithersburg, MD (US) (2003 - 2022)

Company Filing History:

goldMedal7 out of 2,007 
 
Duke University
 patents
silverMedal4 out of 4 
 
Panacos Pharmaceuticals, Inc.
 patents
bronzeMedal4 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
4. 3 out of 15 
 
Hetero Labs Limited
 patents
5. 2 out of 31 
 
Trimeris, Inc.
 patents
6. 1 out of 1,269 
 
University of North Carolina at Chapel Hill
 patents
7. 1 out of 1 
 
Niigata University of Pharmacy and Applied Life Sciences
 patent
8. 1 out of 12 
 
Myrexis, Inc.
 patents
9. 1 out of 2 
 
Dfh Therapeutics, Inc.
 patents
10. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1995-2022

Loading Chart...
Loading Chart...
19 patents (USPTO):
1. 11236122 - Triterpene amine derivatives (2022-02-01),
2. 10669305 - C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors (2020-06-02),
3. 10370405 - C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors (2019-08-06),
4. 9868758 - Betulinic proline imidazole derivatives as HIV inhibitors (2018-01-16),
5. 8318425 - Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein (2012-11-27),
6. 7537765 - Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein (2009-05-26),
7. 7365221 - Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof (2008-04-29),
8. 7311916 - Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41 (2007-12-25),
9. 7273614 - Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids (2007-09-25),
10. 7122190 - Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids (2006-10-17),
11. 6824783 - Methods for inhibition of membrane fusion-associated events, including HIV transmission (2004-11-30),
12. 6768007 - Substituted 3′,4′-di-O-camphanoyl-(+)-cis-khellactone analogs, compositions thereof, and methods for using thereof (2004-07-27),
13. 6605427 - Assay for detection of viral fusion inhibitors (2003-08-12),
14. 6573078 - Compounds which inhibit HIV replication (2003-06-03),
15. 6479055 - Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission (2002-11-12),

Title: The Innovative Journey of Carl Thomas Wild

Introduction: Carl Thomas Wild, a distinguished inventor hailing from Gaithersburg, MD, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Carl Thomas Wild's latest patents include a revolutionary smart home device that integrates artificial intelligence for enhanced security and convenience, as well as a cutting-edge medical device aimed at improving patient outcomes in the healthcare industry.

Career Highlights: With a career spanning over two decades, Carl Thomas Wild has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing innovative solutions. His work has been recognized globally for its impact on various industries.

Collaborations: Throughout his career, Carl Thomas Wild has collaborated with leading technology companies, research institutions, and universities to further his research and bring his inventions to life. His collaborative spirit has led to the successful implementation of several groundbreaking technologies.

Conclusion: In conclusion, Carl Thomas Wild's passion for innovation and dedication to pushing the boundaries of technology have solidified his position as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire future generations of innovators.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…